Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.87)
# 691
Out of 5,046 analysts
229
Total ratings
52.52%
Success rate
9.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Overweight | $163 → $168 | $141.24 | +18.95% | 30 | Oct 20, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $167 → $180 | $136.97 | +31.42% | 11 | Oct 20, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $122 → $129 | $108.88 | +18.48% | 14 | Oct 16, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $65 → $77 | $43.10 | +78.65% | 3 | Sep 29, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $56 → $79 | $41.74 | +89.27% | 5 | Sep 17, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $19 → $18 | $7.19 | +150.35% | 4 | Sep 12, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $76 → $71 | $67.77 | +4.77% | 13 | Aug 20, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Overweight | $35 → $28 | $8.42 | +232.54% | 7 | Aug 18, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $20 → $21 | $10.46 | +100.86% | 4 | Aug 18, 2025 | |
| ERAS Erasca | Downgrades: Equal-Weight | $4 → $2 | $2.41 | -17.01% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $13 | $7.99 | +62.70% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $9.06 | +1,092.05% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $55 | $34.87 | +57.75% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $22.35 | +7.38% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $85.64 | -0.75% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $24.82 | +8.78% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $7.60 | -34.21% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $61.93 | +8.19% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.10 | +392.96% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $1.50 | +166.67% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $1.77 | +125.99% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $6.72 | +108.33% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $4.37 | +14.55% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $2.95 | +1.87% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.83 | +665.03% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.91 | +424.93% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $38.43 | -42.75% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $17.12 | +767.41% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.45 | +4,037.93% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $4.59 | +30.86% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $13.14 | +4,831.51% | 6 | May 8, 2020 |
Neurocrine Biosciences
Oct 20, 2025
Maintains: Overweight
Price Target: $163 → $168
Current: $141.24
Upside: +18.95%
Jazz Pharmaceuticals
Oct 20, 2025
Maintains: Overweight
Price Target: $167 → $180
Current: $136.97
Upside: +31.42%
Rhythm Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $122 → $129
Current: $108.88
Upside: +18.48%
Crinetics Pharmaceuticals
Sep 29, 2025
Maintains: Overweight
Price Target: $65 → $77
Current: $43.10
Upside: +78.65%
CG Oncology
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $41.74
Upside: +89.27%
enGene Holdings
Sep 12, 2025
Maintains: Overweight
Price Target: $19 → $18
Current: $7.19
Upside: +150.35%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $76 → $71
Current: $67.77
Upside: +4.77%
Cullinan Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $8.42
Upside: +232.54%
Contineum Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $10.46
Upside: +100.86%
Erasca
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $2.41
Upside: -17.01%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $7.99
Upside: +62.70%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $9.06
Upside: +1,092.05%
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $34.87
Upside: +57.75%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $22.35
Upside: +7.38%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $85.64
Upside: -0.75%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $24.82
Upside: +8.78%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $7.60
Upside: -34.21%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $61.93
Upside: +8.19%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $7.10
Upside: +392.96%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $1.50
Upside: +166.67%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.77
Upside: +125.99%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $6.72
Upside: +108.33%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $4.37
Upside: +14.55%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $2.95
Upside: +1.87%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.83
Upside: +665.03%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.91
Upside: +424.93%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $38.43
Upside: -42.75%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $17.12
Upside: +767.41%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.45
Upside: +4,037.93%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $4.59
Upside: +30.86%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $13.14
Upside: +4,831.51%